- Predictive
Oncology is working to develop highly customizable assessment methods to
individualize treatment options for cancer, improving outcomes
- POAI’s
innovative technology is pioneering in the field of individualizing
treatment for ovarian cancer
- Predictive
Oncology offers potential for significant ROI as it focuses on improving
outcomes for cancer patients of today and tomorrow
Predictive Oncology Inc. (NASDAQ: POAI) is harnessing
its unique, proprietary database of cancer cases using the proven power of
artificial intelligence (AI) to revolutionize treatment outcomes for cancer
patients. The company works alongside pharmaceutical, diagnostic and biotechnology
industry players to develop highly customizable assessment methods that can be
applied to both individualize current therapies and develop the next generation
of precision therapies, leading to better outcomes for patients. The company
recently announced a corporate name change from Precision Therapeutics to
Predictive Oncology Inc., which reflects its mission and strategic emphasis.
Predictive Oncology seeks to revolutionize the way cancer is
treated for both the patients of today and those of tomorrow. The company is
well positioned to do exactly that as a result of two key assets: its ability
to grow patients’ own tumors in the laboratory and test the tumors’ responses
to chemotherapy, together with its existing database of outcome data cataloguing
more than 150,000 tumors and their specific responses to those chemotherapies.
POAI’s innovative technology enables the company to be a
pioneer in the field of precision oncology, putting the patient at the heart of
both selecting treatments and the development of new treatments. While the use
of AI in precision medicine has been improving oncologists’ ability to diagnose
cancer for several years (http://ibn.fm/ZsmGN),
the ability to accurately prescribe the correct treatment for all but a few
patients has been absent. Applying a guess-and-check methodology, doctors have
limited ability to prescribe the most effective drug to treat patients. This
approach relegates patients with cancer to the role of guinea pigs, trying new
drugs and waiting to see the extent to which they are effective.
Oncologists are realizing that knowledge of genomics, or
simply knowing the genetic markers of a tumor, is not enough to beat cancer.
The ability to better predict which drugs affect certain types of cancer vastly
improves the efficacy of oncologists’ recommendations. This is the void POAI’s
technology can fill.
By utilizing its rich base of data, which includes not only
diagnostic/genomic information but also unique response data which indicates
how certain cancer types have responded to certain drugs, POAI’s predictive
models guide doctors to more effectively individualize therapy. Without having
to wait to discover if the patient responds to a drug, POAI’s technology is
giving cancer patients an earlier indication of efficacy, and hence more
favorable odds for recovery, without squandering their time, a commodity that
many patients don’t have.
In addition, the company has been working with two major
partners to validate its predictive models: Interpace Diagnostics Group Inc.
and UPMC Magee-Women’s Hospital. While primarily utilizing its technology to
create a predictive model for ovarian cancer, POAI’s goal is to grow, applying
its methodologies and leveraging its huge database to impact cancers such as
breast, colon and others.
POAI came about as an acquisition between Skyline Medical
and Helomics. Helomics applies AI to its rich data gathered from patient tumors
to customize cancer therapies for individual patients and drive the development
of new targeted therapies in collaboration with pharmaceutical firms.
In addition, POAI’s TumorGenesis subsidiary is developing a
new rapid approach to growing tumors in the laboratory. This process
essentially “fools” cancer cells into thinking they are still growing inside a
patient. TumorGenesis’ approach is expected to provide a much more relevant
model of patients’ tumors that may be used for testing of drugs, personalized
therapy or the development of new drugs.
Based in Eagan, Minnesota, POAI operates via three business
units: Helomics, TumorGenesis and Skyline Medical. Predictive Oncology
continues to take advantage of the synergies of its subsidiaries to bring
precision medicine to the treatment of cancer. The company is at the vanguard
of innovation in using AI in precision cancer treatment. For investors,
Predictive Oncology offers the potential for significant ROI as it focuses on
improving patient outcomes.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
